Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer

ErbB2, a member of the ErbB family of receptor tyrosine kinases, is an essential player in the cell’s growth and proliferation signaling pathways. Amplification or overexpression of ErbB2 is observed in ∼30% of breast cancer patients, and often drives cellular transformation and cancer development....

Descripción completa

Detalles Bibliográficos
Autores principales: Wolfson, Eya, Solomon, Shira, Schmukler, Eran, Goldshmit, Yona, Pinkas-Kramarski, Ronit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833446/
https://www.ncbi.nlm.nih.gov/pubmed/29352243
http://dx.doi.org/10.1038/s41419-017-0067-7